Acute administration of the RSK inhibitor prevented audiogenic seizures in Fmr1 knock-out mice, indicating that an increased RSK activity contributes to the FXS phenotype and forms a target for therapy [77]. This evidence concerns the gene RPS6KA3 and fragile X syndrome.